Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1990 2
1991 5
1992 1
1993 3
1994 4
1995 5
1996 1
1997 4
1998 7
1999 2
2000 1
2001 3
2002 2
2003 7
2004 2
2005 2
2006 1
2007 2
2008 5
2009 9
2010 8
2011 7
2012 7
2013 12
2014 5
2015 6
2016 10
2017 10
2018 10
2019 7
2020 5
2021 10
2022 7
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Results by year

Filters applied: . Clear all
Page 1
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
Howard JF Jr, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Sivakumar K, Śmiłowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Lowcock R, Vanderkelen M, Leite MI; RAISE Study Team. Howard JF Jr, et al. Lancet Neurol. 2023 May;22(5):395-406. doi: 10.1016/S1474-4422(23)00080-7. Lancet Neurol. 2023. PMID: 37059508 Clinical Trial.
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Howard JF Jr, et al. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.
Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr; Regain Study Group. Muppidi S, et al. Muscle Nerve. 2019 Jul;60(1):14-24. doi: 10.1002/mus.26447. Epub 2019 Mar 8. Muscle Nerve. 2019. PMID: 30767274 Free PMC article.
A report from the SIdEM: Italy.
Ostuni A, Accorsi P, Mazzoni A, Vacca M, Colpo A, Agostini V, Crovetti G, Iuliani O, Michelotti A, Rondinelli MB, Zanella A, Antozzi C, De Silvestro G, Lanza F, Montanari M, Trinchero M; SIdEM Corporate Offices. Ostuni A, et al. Among authors: antozzi c. Transfus Apher Sci. 2023 Aug;62(4):103761. doi: 10.1016/j.transci.2023.103761. Epub 2023 Jul 15. Transfus Apher Sci. 2023. PMID: 37495449 No abstract available.
Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study.
Antozzi C, Guptill J, Bril V, Gamez J, Meuth SG, Nowak RJ, Quan D, Sevilla T, Jouvin MH, Jin J, Karcher K, Ramchandren S, Sun H, Ling L, Zhu Y, Arroyo S; Vivacity-MG Phase 2 Study Group. Antozzi C, et al. Neurology. 2024 Jan 23;102(2):e207937. doi: 10.1212/WNL.0000000000207937. Epub 2023 Dec 21. Neurology. 2024. PMID: 38165333 Free PMC article. Clinical Trial.
Efgartigimod improves triple-negative myasthenia gravis.
Frangiamore R, Rinaldi E, Vanoli F, Andreetta F, Mantegazza R, Antozzi C. Frangiamore R, et al. Among authors: antozzi c. Neurol Sci. 2024 Mar;45(3):1307-1309. doi: 10.1007/s10072-023-07122-y. Epub 2023 Oct 24. Neurol Sci. 2024. PMID: 37875596 No abstract available.
Mitochondrial disorders.
Zeviani M, Antozzi C. Zeviani M, et al. Among authors: antozzi c. Mol Hum Reprod. 1997 Feb;3(2):133-48. doi: 10.1093/molehr/3.2.133. Mol Hum Reprod. 1997. PMID: 9239718 Review.
166 results